| __timestamp | Geron Corporation | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 1499100000 |
| Thursday, January 1, 2015 | 17793000 | 1923500000 |
| Friday, January 1, 2016 | 18761000 | 2351400000 |
| Sunday, January 1, 2017 | 19287000 | 2564000000 |
| Monday, January 1, 2018 | 18707000 | 2397300000 |
| Tuesday, January 1, 2019 | 20893000 | 2503400000 |
| Wednesday, January 1, 2020 | 25678000 | 3344600000 |
| Friday, January 1, 2021 | 29665000 | 4529200000 |
| Saturday, January 1, 2022 | 43628000 | 4179100000 |
| Sunday, January 1, 2023 | 69135000 | 4650100000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. From 2014 to 2023, Viatris Inc. and Geron Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Viatris Inc., a major player, has consistently outpaced Geron Corporation, with its SG&A expenses growing from approximately $1.5 billion in 2014 to nearly $4.65 billion in 2023. This represents a staggering 210% increase over the decade. In contrast, Geron Corporation's SG&A expenses rose from $16.8 million to $69.1 million, marking a 311% increase. While both companies have increased their spending, Viatris's scale is significantly larger, reflecting its expansive operations. These trends highlight the strategic financial decisions each company has made in response to market demands and growth opportunities.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.